MedTrace Logo

The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy

NCT01121497 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2010-05-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether the administration of physostigmine in combination with sedation for colonoscopy can minimize the cognitive decline at the time of hospital discharge

Conditions

  • Cognitive Dysfunction

Interventions

DRUG

Physostigmine

Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Bezion Beilin, MD · Hasharon Hospital, Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121497 on ClinicalTrials.gov